重组人脑利钠肽与硝普钠治疗充血性心力衰竭的临床观察

目的:比较重组人脑利钠肽与硝普钠治疗急性失代偿性心力衰竭的治疗效果和安全性。方法:对入选的148例急性失代偿性心衰患者的临床资料随机分为试验组74例,对照组74例,在常规治疗基础上分别予重组人脑利钠肽(新活素)、硝普钠,3天后判断疗效。结果:临床状况好转率的比较,试验组显著优于对照组(P<0.05),LVEF(左室射血分数)及尿量改善试验组高于对照组。结论:重组人脑利钠肽能明显改善急性失代偿性心衰患者的血流动力学,在全身临床状况方面优于硝普钠,其安全性与硝普钠类似。

Objective： To compare recombinant human brain natriuretic peptide and sodium nitroprusside treatment of acute decompensated heart failure. Methods：The experiment on the candidates of the 148 patients with acute decompensated heart failure in patients with clinical data of 74 patients were randomly divided into experimental group and control group 74 cases, respectively. In the conventional therapy to recombinant human brain natriuretic peptide （new live prime）, sodium nitroprusside. Judge the effect on 3rd day. Results： improved the rate of clinical status compared to the experimental group was significantly better than the control group （P 〈 0.05）, LVEF （left ventricular ejection fraction ）, and urine to improve the experimental group, control group. Conclusion of recombinant human brain natriuretic peptide can significantly improve the acute decompensated heart failure in patients with hemodynamics, clinical status of the body is superior to sodium nitroprusside, which is similar security and sodium nitroprusside.